{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitomycin+C+%28MMC%29", "query": { "intervention": "Mitomycin C (MMC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 133, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitomycin+C+%28MMC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T21:34:53.455Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05243550", "title": "A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma", "Urothelial Carcinoma Bladder" ], "interventions": [ { "name": "UGN-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UroGen Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2022-03-01", "completion_date": "2028-03", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 16, "location_summary": "Tucson, Arizona • Loma Linda, California • San Diego, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243550" }, { "nct_id": "NCT00271011", "title": "A Study of Mitomycin C, Irinotecan, and Cetuximab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Mitomycin C", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2005-12", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00271011" }, { "nct_id": "NCT02040142", "title": "HIPEC for Peritoneal Carcinomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peritoneal Carcinomatosis", "Colorectal Cancer", "Appendiceal Cancer", "Peritoneal Mesothelioma", "Pseudomyxoma Peritonei", "Gastric Cancer" ], "interventions": [ { "name": "HIPEC", "type": "PROCEDURE" }, { "name": "Mitomycin C", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2011-11", "completion_date": "2024-08-19", "has_results": true, "last_update_posted_date": "2024-10-24", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02040142" }, { "nct_id": "NCT04166318", "title": "Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Basaloid Carcinoma", "Anal Canal Cloacogenic Carcinoma", "Anal Canal Squamous Cell Carcinoma", "Anal Margin Squamous Cell Carcinoma", "Stage I Anal Cancer AJCC v8", "Stage IIA Anal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2020-01-02", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 659, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04166318" }, { "nct_id": "NCT01115517", "title": "Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pterygium" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Mitomycin C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 51, "start_date": "2010-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01115517" }, { "nct_id": "NCT06822010", "title": "SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Cancer", "Upper Tract Urothelial Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 28, "start_date": "2026-03-06", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06822010" }, { "nct_id": "NCT01167725", "title": "Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mitomycin C", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 340, "start_date": "2010-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167725" }, { "nct_id": "NCT02311101", "title": "Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasm" ], "interventions": [ { "name": "Mitomycin C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311101" }, { "nct_id": "NCT02788201", "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer", "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "75 approved agents", "type": "DRUG" }, { "name": "COXEN", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-03-27", "completion_date": "2019-10-23", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788201" }, { "nct_id": "NCT05672108", "title": "Phase II Trial of Lung Chemoemobolization", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Mediastinal Neoplasm", "Pleural Neoplasm", "Lung Metastases From Any Primary", "Endobronchial Metastases", "Colon Cancer", "Sarcoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ethiodized Oil", "type": "DRUG" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Transarterial Chemoembolization", "type": "PROCEDURE" }, { "name": "Tris-acryl Gelatin Microspheres", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-05-12", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-24T21:34:53.455Z", "location_count": 2, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672108" } ] }